Articles
Publications
Reach out to us for your interest in our technology
Cardioneuroablation Using Epicardial Pulsed Field Ablation for the Treatment of Atrial Fibrillation
Review
B O’Brien, J Reilly, K Coffey et al
J. Cardiovasc. Dev. Dis. 2023.
B O’Brien, J Reilly, K Coffey et al
J. Cardiovasc. Dev. Dis. 2023.
The background and development of cardioneuroablation techniques are presented in the context of AtriAN’s therapy. An overview of key work is presented, covering in vitro studies, electric field models, pre-clinical research and clinical trials. Future work and applications are discussed.
Epicardial Pulsed Field Ablation of Ganglionated Plexi: Computational and Pre-Clinical Evaluation of a Bipolar Sub-Xiphoid Catheter for the Treatment of Atrial Fibrillation
Pre-Clinical
B O’Brien, J Reilly, K Coffey et al
Bioengineering 2024.
B O’Brien, J Reilly, K Coffey et al
Bioengineering 2024.
This paper presents electric field models and ablation studies for the prototype bipolar and subxiphoid device – both porcine and canine models were used. Acute extensions in atrial effective refractory period suggest that ablations efficacy is at least equivalent to the monopolar device that has already been used in open-chest clinical settings. Ablation of neuronal cells, within the epicardial ganglionated plexi, was confirmed through histology.
Open-chest Pulsed Electric Field Ablation of Cardiac Ganglionated Plexi in Acute Canine Models
Pre-Clinical
M van Zyl, M Khabsa, JA Tri et al
J Innov Cardiac Rhythm Manage 2022.
This open-chest study was performed as full system validation before progressing to first-in-human open-chest clinical trials. It’s utilized AtriAN’s cardiac-customized pulsed field generator and devices designed specifically for open-chest epicardial treatment. Acute extensions in atrial effective refractory period (AERP) were demonstrated as well as evidence of reversible electroporation in myocardial tissue.